Patentes
-
Atrial fibrillation is an irregular and often very fast heartbeat that can cause the formation of blood clots in the heart, increasing the risk of stroke, heart failure, and related complications. Atrial fibrillation condition affects an estimated 10 million people in Europe, and around 700,000 in Spain.
Atrial fibrillation is currently classified according to the length of time that the patient has been in arrhythmia. This temporal classification provides no information about a patient’s extent of atrial remodeling, an especially important parameter in the first months of the condition, when the underlying disease processes can progress at different rates.
A multidisciplinary study led by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) presents a new method for assessing the structural and electrophysiological changes, called atrial remodeling, produced in the heart of patients with atrial fibrillation, one of the most frequent forms of cardiac arrhythmia. The new diagnostic method is based on the simultaneous assessment of electrical and mechanical (contractile) activity in the heart atria during atrial fibrillation.
The importance of this new diagnostic method is its ability to provide a personalized assessment of an individual patient’s degree of atrial remodeling, independently of the clinical classification based on temporal criteria.
A key advantage of the new approach is that atrial electromechanical dissociation is identified before the appearance of overt clinical signs of structural atrial remodeling. The use of this new diagnostic approach allows early characterization of the underlying remodeling in patients with atrial fibrillation. The study shows that it is possible to integrate electrical and mechanical data from the atria of patients with atrial fibrillation to obtain personalized prognostic information about the clinical progression of the disease.
NúmeroPCT/EP2022/071364Fecha de prioridad30/07/2021TitularesCNICInventoresDavid Filgueiras Rama, Jorge García Quintanilla, Javier Sánchez -
La fibrilación auricular es un ritmo cardíaco irregular y a menudo muy rápido que puede provocar coágulos de sangre en el corazón y que aumenta el riesgo de accidente cerebrovascular, insuficiencia cardíaca y otras complicaciones relacionadas con el corazón. La fibrilación auricular afecta a unos 10 millones de personas en Europa y alrededor de 700.000 en España.
La clasificación de los pacientes con fibrilación auricular se basa fundamentalmente en criterios temporales en función del tiempo que el paciente ha estado con la arritmia. Dicha clasificación temporal no permite determinar el grado de remodelado subyacente de un paciente en concreto, lo cual tiene especial importancia en los primeros meses de evolución de la fibrilación auricular cuando el grado de avance de los procesos patológicos subyacentes puede seguir distintas velocidades de progresión.
Un trabajo multidisciplinar dirigido por el Centro Nacional de Investigaciones Cardiovasculares (CNIC) ha permitido el desarrollo de un nuevo abordaje para valorar los cambios estructurales y electrofisiológicos que se producen en el corazón, denominados remodelado auricular, de pacientes con un tipo de arritmia muy frecuente, la fibrilación auricular. Esta nueva aproximación diagnóstica se basa en la evaluación de forma simultánea de la actividad eléctrica y mecánica (contráctil) de las aurículas durante fibrilación auricular.
La relevancia de este nuevo abordaje diagnóstico se pone de manifiesto en su capacidad para hacer una evaluación personalizada del grado de avance del remodelado auricular en un paciente en concreto, más allá de la clasificación clínica basada en un criterio temporal.
La identificación de la disociación electromecánica auricular ocurre antes de que otros parámetros de remodelado se hayan puesto de manifiesto y por lo tanto, pasen desapercibidos durante una evaluación clínica rutinaria o con herramientas convencionales. El uso de esta nueva aproximación diagnóstica permite una caracterización precoz del grado de remodelado subyacente de los pacientes con fibrilación auricular. El estudio demuestra que es posible integrar la información eléctrica y mecánica de las aurículas de los pacientes en fibrilación auricular y así obtener información pronóstica personalizada con respecto a la evolución clínica de la arritmia.NúmeroPCT/EP2022/071364Fecha de prioridad30/07/2021TitularesCNICInventoresDavid Filgueiras Rama, Jorge García Quintanilla, Javier Sánchez -
Atrial fibrillation (AF), one of the most frequent types of arrhythmias, affects more than 30 million people worldwide and, in Spain, it is estimated that there are more than 600,000. In addition, it is also estimated that around 37% of the world's population over the age of 40 will suffer from it in their lifetime. Ablation (isolation of the pulmonary veins of the left atrium) with a catheter, aimed at isolating the pulmonary veins of the left atrium, is the conventional therapy for this disease when it does not respond to drug therapy. However, ablation offers suboptimal results in complex cases of AF because other regions of the atria, beyond the pulmonary veins, are also relevant to the maintenance of the arrhythmia. This is especially true in cases of persistent AF with months or years of evolution.
Researchers from the CNIC and HCSC have developed a system to guide ablation procedures in a patient-specific way in complex cases of persistent atrial fibrillation, identifying these key regions to be treated with great precision and specificity. Furthermore, it does not require additional equipment or consumables, but only software that could be implemented within any conventional electroanatomical browser, so it would not make current pulmonary vein isolation procedures more expensive, with the advantage of being able to perform patient-specific ablation in complex cases.
The intellectual property developed in CNIC (related to this project) to efficiently identify and target atrial fibrillation drivers during persistent atrial fibrillation is under further clinical assessment in the ongoing TAILOR-AF study (NCT05169320) conducted at the Hospital Clínico San Carlos (co-owner of the intellectual property). The main objective of this study is to identify (via iAM/iFM maps), target and ablate atrial fibrillation leading drivers in patients with symptomatic persistent atrial fibrillation recurrences despite ≥2 previous pulmonary vein isolation procedures. The methods include a percutaneous catheter mapping and ablation approach followed by a minimally invasive surgical approach via thoracoscopy, if necessary. As a secondary objective we will study the association of underlying blood biomarkers, atrial imaging and surface ECG parameters, with advanced remodeling stages requiring a surgical approach to target leading driver regions. This study illustrates the strong motivation of the laboratory to achieve clinical impact with the research activities performed in animal models.
NúmeroEP3863510B1; US17/284,195Fecha de prioridad11/10/2018TitularesCNIC, HCSCInventoresJorge García Quintanilla, David Filgueiras Rama, Nicasio Pérez Castellano, Julián Pérez-Villacastín Domínguez -
La fibrilación auricular (FA), uno de los tipos de arritmias más frecuentes, afecta a más de 30 millones de personas en todo el mundo y, en España, se estima que hay más de 600.000. Además, se calcula que alrededor del 37% de la población mundial mayor de 40 años la padecerá en el transcurso de su vida. La ablación (aislamiento de las venas pulmonares de la aurícula izquierda) con catéter, dirigida al aislamiento de las venas pulmonares de la aurícula izquierda, es la terapia convencional de esta enfermedad cuando no responde a fármacos. Sin embargo, la ablación ofrece resultados subóptimos en casos complejos de FA debido a que otras regiones de las aurículas, más allá de las venas pulmonares, también son relevantes para el mantenimiento de la arritmia. Esto ocurre especialmente en casos de FA persistente con meses o años de evolución.
Investigadores del CNIC y HCSC han desarrollado un sistema que permite guiar procedimientos de ablación de una forma específica para cada paciente en casos complejos de fibrilación auricular persistente, identificando estas regiones clave a tratar con gran precisión y especificidad. Además, no requiere equipos ni material fungible adicional, sino sólo un software que podría implementarse dentro de cualquier navegador electroanatómico convencional, por lo que no encarecería los procedimientos actuales de aislamiento de venas pulmonares, con la ventaja de poder realizar una ablación paciente-específica en casos complejos.
The intellectual property developed in CNIC (related to this project) to efficiently identify and target atrial fibrillation drivers during persistent atrial fibrillation is under further clinical assessment in the ongoing TAILOR-AF study (NCT05169320) conducted at the Hospital Clínico San Carlos (co-owner of the intellectual property). The main objective of this study is to identify (via iAM/iFM maps), target and ablate atrial fibrillation leading drivers in patients with symptomatic persistent atrial fibrillation recurrences despite ≥2 previous pulmonary vein isolation procedures. The methods include a percutaneous catheter mapping and ablation approach followed by a minimally invasive surgical approach via thoracoscopy, if necessary. As a secondary objective we will study the association of underlying blood biomarkers, atrial imaging and surface ECG parameters, with advanced remodeling stages requiring a surgical approach to target leading driver regions. This study illustrates the strong motivation of the laboratory to achieve clinical impact with the research activities performed in animal models.
NúmeroEP3863510B1; US17/284,195Fecha de prioridad11/10/2018TitularesCNIC, HCSCInventoresJorge García Quintanilla, David Filgueiras Rama, Nicasio Pérez Castellano, Julián Pérez-Villacastín Domínguez -
Background
Telomere fusions (TFs) can lead to genomic rearrangements and have been shown to play a critical role in several types of cancer. Despite their relevance in oncology, a deeper understanding of TFs in human cancer remains limited. On the other hand, the detection of tumours in the earliest state possible is absolutely critical for treatment and prognosis of cancer.
Technology Overview
Scientists at EMBL-EBI, CNIC and CSIC have discovered a new type of telomere fusion that is not present in blood from healthy donors but can be detected well in the blood of cancer patients. They developed computational tools for the reliable identification of these fusions. Additionally, predictive models have been established that allow for the detection of the presence of a tumour using sequencing data from a blood sample. We hereby present an approach for a highly specific, minimally invasive and early detection of cancer. The sensitivity and false positive rate are comparable to recent liquid biopsy analysis methods. The performance of the tools is comparable across cancer stages. The tool has been validated using close to 10,000 whole genome sequencing datasets.
Further Details
Francesc Muyas, Manuel José Gómez Rodriguez, Isidro Cortes-Ciriano, Ignacio Flores. “The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients“, doi: https://doi.org/10.1101/2022.01.25.477771More info and contact: https://embl-em.portals.in-part.com/vJe06G6X7mKG?utm_source=technologies&utm_medium=portal&utm_term=latestBenefits- Good sensitivity and false positive rates values tested in more than 10,000 cancer samples- Very good sensitivity- Very high specificity- Similar performances across different stages, highlighting the potential of early detection of tumors in liquid biopsyApplications
The final goal is to develop a cancer screening and monitoring kit and a cloud-based computational solution for data analysis, thus allowing decentralized, fast and cheap analyses.
Opportunity
The technology is available for out-licensing or co‑development. EMBL Heidelberg also offers a technology evaluation program.
NúmeroPCT/EP2022/087821Fecha de prioridad23/12/2021TitularesEMBL-EBI, CNIC, CSICInventoresIsidro Cortés-Ciriano, Francesc Muyas Remolar, Ignacio Flores Hernández, Manuel José Gómez Rodríguez -
Background
Telomere fusions (TFs) can lead to genomic rearrangements and have been shown to play a critical role in several types of cancer. Despite their relevance in oncology, a deeper understanding of TFs in human cancer remains limited. On the other hand, the detection of tumours in the earliest state possible is absolutely critical for treatment and prognosis of cancer.
Technology Overview
Scientists at EMBL-EBI, CNIC and CSIC have discovered a new type of telomere fusion that is not present in blood from healthy donors but can be detected well in the blood of cancer patients. They developed computational tools for the reliable identification of these fusions. Additionally, predictive models have been established that allow for the detection of the presence of a tumour using sequencing data from a blood sample. We hereby present an approach for a highly specific, minimally invasive and early detection of cancer. The sensitivity and false positive rate are comparable to recent liquid biopsy analysis methods. The performance of the tools is comparable across cancer stages. The tool has been validated using close to 10,000 whole genome sequencing datasets.
Further Details
Francesc Muyas, Manuel José Gómez Rodriguez, Isidro Cortes-Ciriano, Ignacio Flores. “The ALT pathway generates telomere fusions that can be detected in the blood of cancer patients“, doi: https://doi.org/10.1101/2022.01.25.477771More info and contact: https://embl-em.portals.in-part.com/vJe06G6X7mKG?utm_source=technologies&utm_medium=portal&utm_term=latestBenefits- Good sensitivity and false positive rates values tested in more than 10,000 cancer samples- Very good sensitivity- Very high specificity- Similar performances across different stages, highlighting the potential of early detection of tumors in liquid biopsyApplications
The final goal is to develop a cancer screening and monitoring kit and a cloud-based computational solution for data analysis, thus allowing decentralized, fast and cheap analyses.
Opportunity
The technology is available for out-licensing or co‑development. EMBL Heidelberg also offers a technology evaluation program.
NúmeroPCT/EP2022/087821Fecha de prioridad23/12/2021TitularesEMBL-EBI, CNIC, CSICInventoresIsidro Cortés-Ciriano, Francesc Muyas Remolar, Ignacio Flores Hernández, Manuel José Gómez Rodríguez -
La hipertensión pulmonar (HP), definida como el aumento de la presión sanguínea pulmonar media por encima de los valores normales, abarca una serie de trastornos caracterizados por el aumento de la resistencia vascular pulmonar y el deterioro progresivo del ventrículo derecho. La incidencia de la hipertensión pulmonar en la población es elevada y se asocia con una alta morbilidad y mortalidad. Aproximadamente dos tercios de los pacientes con disfunción ventricular izquierda (sistólica o diastólica aislada) desarrollan hipertensión pulmonar. Actualmente, hay una falta de tratamientos para la hipertensión pulmonar.
Los investigadores del CNIC y de CLINIC han descrito un nuevo tratamiento efectivo para la hipertensión pulmonar de diferente etiología, tanto crónica como aguda. Han descubierto que la estimulación selectiva de los receptores adrenérgicos beta-3 tiene un efecto beneficioso en la hipertensión pulmonar.
Artículo científico: https://doi.org/10.1002/ejhf.2745
NúmeroEP2891490B1, US10532038B2Fecha de prioridad29/08/2012TitularesCNIC, CLINICInventoresBorja Ibáñez Cabeza, Valentín Fuster Carulla, Ana García-Álvarez -
Pulmonary hypertension (PH), defined as the increase of mean pulmonary blood pressure above normal values, encompasses a series of disorders characterized by the increase of pulmonary vascular resistance and progressive deterioration of the right ventricle. The incidence of pulmonary hypertension in the population is high and it is associated with high morbidity and mortality. Approximately two thirds of patients with left ventricular dysfunction (systolic or isolated diastolic) develop pulmonary hypertension. Currently, there is a lack of treatments for pulmonary hypertension.
CNIC and CLINIC researchers have described a novel effective treatment for pulmonary hypertension of different etiology, both chronic and acute. They have found that selective stimulation of beta-3 adrenergic receptors has a beneficial effect in pulmonary hypertension.
Scientific article: https://doi.org/10.1002/ejhf.2745
NúmeroEP2891490B1, US10532038B2Fecha de prioridad29/08/2012TitularesCNIC, CLINICInventoresBorja Ibáñez Cabeza, Valentín Fuster Carulla, Ana García-Álvarez -
Los nuevos biomarcadores de aterosclerosis buscan mejorar el diagnóstico y pronóstico de esta enfermedad. El CNIC, en colaboración con investigadores del DKFZ han descubierto una familia de 18 anticuerpos que presentan reactividad frente a la placa de ateroma, de tal manera que se podrían utilizar para diagnosticar la enfermedad. Además, la administración del anticuerpo A12 previene la progresión de la aterosclerosis y reduce los niveles de colesterol libre y LDL.
Artículo científico: https://doi.org/10.1038/s41586-020-2993-2
NúmeroEP20786476Fecha de prioridad23/09/2019TitularesCNIC, DKFZInventoresAlmudena Rodríguez Ramiro, Cristina Lorenzo Martín, Hedda Wardemann, Christian Busse -
Novel atherosclerosis biomarkers are in need to improve the strategies for diagnosis and prognosis of cardiovascular disease. CNIC and DKFZ researchers have discovered 18 novel antibodies that show reactivity against the atherosclerotic plaque, which can thus be potentially used for the diagnosis of this disease. Moreover, the use of one such antibody, A12, delays the progression of atherosclerosis and reduces the level of free circulating cholesterol and LDL.
Scientific article: https://doi.org/10.1038/s41586-020-2993-2
NúmeroEP20786476Fecha de prioridad23/09/2019TitularesCNIC, DKFZInventoresAlmudena Rodríguez Ramiro, Cristina Lorenzo Martín, Hedda Wardemann, Christian Busse
